BioMedomics Inc.

Jiangsu Medomics Medical Technology Co.,Ltd., established in October 2017 and located in Biotech and Pharmaceutical Valley, National Jiangbei New Area, Nanjing, Jiangsu Province, is an innovation-driven international high-tech enterprise of medical devices. Medomics focuses on the early accurate medical treatment of microorganisms, tumors and some rare diseases. It is mainly engaged in the research & development, production and sale of in vitro diagnostic reagents and supporting automatic instruments. In the early stage of COVID-19 outbreak in 2020, Medomics quickly responded to the call of the National Health Commission of the People’s Republic of China, developed the COVID-19 antibody detection kit in the shortest time by gathering research & development forces and cooperating with the Academician Zhong Nanshan’s Team, and issued the first relevant paper in an international journal by cooperating with the Institute of Respiratory Health (State Key Laboratory of Respiratory Disease). The products produced by it passed the tests of Chinese Center for Disease Control and Prevention, Harvard Medical School, Columbia University College of Physicians and Surgeons, and other institutions. By May 2020, the antibody detection kit of Medomics had been exported to more than 40 countries and regions accumulatively, making contributions to the global combat against the “epidemic”.